TABLE OF CONTENT: 1. Introduction 1. Research Scope 2. Market Segmentation 3. Research Methodology 4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 1. Market Drivers 2. Market Restraints 3. Market Opportunities 4. Key Insights 1. Prevalence of Key Mucopolysaccharidosis Types - by key regions (2018) 2. Pipeline Analysis 3. Key Industry Developments 4. Regulatory Scenario- by Key Regions 5. Overview of Emerging Treatments for Mucopolysaccharidosis 6. Reimbursement Scenario - by Key Regions 5. Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026 1. Key Findings / Summary 2. Market Analysis, Insights and Forecast – By Treatment 1. Enzyme Replacement Therapy (ERT) 2. Others 3. Market Analysis, Insights and Forecast – By Disease Type 1. Mucopolysaccharidosis Type I 2. Mucopolysaccharidosis Type II 3. Mucopolysaccharidosis Type IV A 4. Mucopolysaccharidosis Type VI 5. Others 4. Market Analysis, Insights and Forecast – By Route of Administration 1. Intravenous 2. Intracerebroventricular (ICV) 5. Market Analysis, Insights and Forecast – By End User 1. Hospitals 2. Specialty Clinics 3. Others 6. Market Analysis, Insights and Forecast – By Region 1. North America 2. Europe 3. Asia pacific 4. Rest of the World 6. North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026 1. Key Findings / Summary 2. Market Analysis – By Treatment 1. Enzyme Replacement Therapy (ERT) 2. Others 3. Market Analysis – By Disease Type 1. Mucopolysaccharidosis Type I 2. Mucopolysaccharidosis Type II 3. Mucopolysaccharidosis Type IV A 4. Mucopolysaccharidosis Type VI 5. Others 4. Market Analysis – By Route of Administration 1. Intravenous 2. Intracerebroventricular (ICV) 5. Market Analysis – By End User 1. Hospitals 2. Specialty Clinics 3. Others 6. Market Analysis – By Country 1. U.S. 2. Canada 7. Europe Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026 1. Key Findings / Summary 2. Market Analysis – By Treatment 1. Enzyme Replacement Therapy (ERT) 2. Others 3. Market Analysis – By Disease Type 1. Mucopolysaccharidosis Type I 2. Mucopolysaccharidosis Type II 3. Mucopolysaccharidosis Type IV A 4. Mucopolysaccharidosis Type VI 5. Others 4. Market Analysis – By Route of Administration 1. Intravenous 2. Intracerebroventricular (ICV) 5. Market Analysis – By End User 1. Hospitals 2. Specialty Clinics 3. Others 6. Market Analysis – By Country/ sub-region 1. U.K. 2. Germany 3. France 4. Spain 5. Italy 6. Rest of Europe 8. Asia Pacific Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026 1. Key Findings / Summary 2. Market Analysis – By Treatment 1. Enzyme Replacement Therapy (ERT) 2. Others 3. Market Analysis – By Disease Type 1. Mucopolysaccharidosis Type I 2. Mucopolysaccharidosis Type II 3. Mucopolysaccharidosis Type IV A 4. Mucopolysaccharidosis Type VI 5. Others 4. Market Analysis – By Route of Administration 1. Intravenous 2. Intracerebroventricular (ICV) 5. Market Analysis – By End User 1. Hospitals 2. Specialty Clinics 3. Others 6. Market Analysis – By Country/ sub-region 1. Japan 2. China 3. India 4. South Korea 5. Rest of Asia Pacific 9. Rest of the World Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026 1. Key Findings / Summary 2. Market Analysis – By Treatment 1. Enzyme Replacement Therapy (ERT) 2. Others 3. Market Analysis – By Disease Type 1. Mucopolysaccharidosis Type I 2. Mucopolysaccharidosis Type II 3. Mucopolysaccharidosis Type IV A 4. Mucopolysaccharidosis Type VI 5. Others 4. Market Analysis – By Route of Administration 1. Intravenous 2. Intracerebroventricular (ICV) 5. Market Analysis – By End User 1. Hospitals 2. Specialty Clinics 3. Others 10. Competitive Analysis 1. Key Industry Developments 2. Global Market Share Analysis (2017) 3. Competition Dashboard 4. Comparative Analysis – Major Players 5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability)) 1. Shire (Takeda Pharmaceutical Company Limited) 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 2. Denali Therapeutics 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 3. ArmaGen 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 4. REGENXBIO Inc. 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 5. Sangamo Therapeutics 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 6. BioMarin 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 7. Lysogene 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 8. Abeona Therapeutics Inc. 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 9. Ultragenyx Pharmaceutical 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability) 10. Genzyme Corporation 1. Overview, 2. Products & services, 3. SWOT analysis, 4. Recent developments, 5. strategies, 6. financials (based on availability)

Shire (Takeda Pharmaceutical Company Limited) Denali Therapeutics ArmaGen REGENXBIO Inc. Sangamo Therapeutics BioMarin Lysogene Abeona Therapeutics Inc. Ultragenyx Pharmaceutical Genzyme Corporation Others